Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.
Nobody likes tariffs, says Jim Cramer. But Trump said he'd do it. Even so, trade and tariff fears have hit Wall Street -- and investors -- hard.
These biotech names are all great buys on dips. Notably Celgene, which is fresh off a terrible trading session.